FLORHAM PARK, N.J. - Cellectar Biosciences Inc. (NASDAQ:CLRB) announced subset analysis results from its Phase 2 CLOVER WaM clinical trial of iopofosine I 131 for treating relapsed or refractory Waldenström macroglobulinemia.
The analysis examined 24 patients who received iopofosine I 131 immediately following Bruton Tyrosine Kinase inhibitor therapy. Results showed a 79.2% major response rate and a median duration of response of 16 months.
Overall response rate was 87.5%, and clinical benefit rate was 100%. Twenty percent of patients exceeded 30 months duration of response.
The company plans to pursue accelerated approval in the US and initiate a confirmatory Phase 3 study in Q4 2026.
